Luke Evnin, Director at Werewolf Therapeutics, Inc. (HOWL), sold 407,574 shares at $0.70 ($280K) on 2026-05-08, disclosed to the SEC on 2026-05-12.
Scheduled sale ($280k) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $0.70 | 305,741 | $214K | 76.4% |
| 2 | $0.67 | 33,948 | $23K | 8.1% |
| 3 | $0.64 | 67,885 | $43K | 15.5% |
| Total | $0.69 avg | 407,574 | $280K | 100% |
| Filing → |
| HOWL | SELL | 2026-06-10 | $28K | — | Filing → |
| HOWL | SELL | 2026-06-08 | $43K | — | Filing → |
| HOWL | SELL | 2026-06-03 | $64K | — | Filing → |